Abstracts tagged "Idiopathic Inflammatory Myopathies (IIM) and myositis"

Abstract Number: 1341 • 2018 ACR/ARHP Annual Meeting
Autoantibodies to Mi-2 Alpha and Mi-2 Beta in Patients with Myositis
Michaelin Richards¹, Ignacio Garcia-De La Torre², Yelitza Gonzalez-Bello³, Monica Vazquez-Del Mercado⁴, Lilia Andrade-Ortega⁵, Gabriel Medrano-Rameriz⁶, Jose Eduardo Navarro-Zarza⁷, Marco Maradiaga⁸, Esthela Loyo⁹, Armando Rojo-Mejía¹⁰, Graciela N Gómez¹¹, Andrea Seaman¹, Marvin J. Fritzler¹², Martial Koenig¹³ and Michael Mahler¹, ¹Research and Development, Inova Diagnostics, San Diego, CA, ²Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ³Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Guadalajara, Jalisco, Mexico, ⁴Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Rheumatology Department, CMN 20 de Noviembre ISSSTE,, CDMX, Mexico, ⁶Hospital General de México, "Dr. Eduardo Liceaga, Mexico City, Mexico, ⁷Hospital General “Dr. Raymundo Abarca Alarcón”, Chilpancingo, Mexico, ⁸Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁹Departamento de Reumatologia, Hospital Regional Universitario José Ma Cabral Baez, Santiago, Dominican Republic, ¹⁰Clínica San Pablo, Lima, Peru, ¹¹Diaz Colodrero 2537 8° A, Instituto de Investigaciones Medicas Alfredo Lanari, Capital Federal, Argentina, ¹²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹³Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Myositis specific antibodies (MSA) represent not only important diagnostic tools, but also help stratify myositis patients with particular clinical features, treatment responses and disease…
Abstract Number: 1342 • 2018 ACR/ARHP Annual Meeting
Myositis Specific Antibodies Measured Using a Novel Particle Based Multi-Analyte Assay Resemble Myositis Subsets By Principle Component Analysis
Michaelin Richards¹, Ignacio Garcia de la Torre², Yelitza Gonzalez-Bello³, Monica Vazquez-Del Mercado⁴, Lilia Andrade-Ortega⁵, Gabriel Medrano-Rameriz⁶, Jose Eduardo Navarro-Zarza⁷, Marco Maradiaga⁸, Esthela Loyo⁹, Armando Rojo-Mejía¹⁰, Graciela N Gómez¹¹, Andrea Seaman¹, Marvin J. Fritzler¹² and Michael Mahler^1,13, ¹Research and Development, Inova Diagnostics, San Diego, CA, ²Hospital General de Occidente, Guadalajara, Mexico, ³Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Guadalajara, Jalisco, Mexico, ⁴Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Rheumatology Department, CMN 20 de Noviembre ISSSTE,, CDMX, Mexico, ⁶Hospital General de México, "Dr. Eduardo Liceaga, Mexico City, Mexico, ⁷Hospital General “Dr. Raymundo Abarca Alarcón”, Chilpancingo, Mexico, ⁸Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁹Departamento de Reumatologia, Hospital Regional Universitario José Ma Cabral Baez, Santiago, Dominican Republic, ¹⁰Clínica San Pablo, Lima, Peru, ¹¹Diaz Colodrero 2537 8° A, Instituto de Investigaciones Medicas Alfredo Lanari, Capital Federal, Argentina, ¹²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹³9900 Old Grove road, INOVA Diagnostics, San Diego, CA
Background/Purpose: Myositis specific antibodies (MSA) represent important diagnostic tools and also help stratify idiopathic inflammatory myositis (IIM) patients with particular clinical features, treatment responses, and…
Abstract Number: 1232 • 2015 ACR/ARHP Annual Meeting
Prevalence of Idiopathic Inflammatory Myopathies in Sweden in 2012 – a National Register Study
John Svensson¹, Anna Tjärnlund², Ingrid E. Lundberg³ and Marie Holmqvist⁴, ¹Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Medicine, Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet S-171 76, Stockholm, Sweden, Stockholm, Sweden, ⁴Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Overall prevalence of idiopathic inflammatory myopathies (IIM) is commonly reported at 10 per 100,000 but worldwide estimates vary between 1 and 25 per 100,000…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].